Quelles sont les complications possibles du traitement adjuvant ?
Des complications comme infections, fatigue chronique et troubles sanguins peuvent survenir.
ComplicationsInfectionsFatigue chronique
#2
Comment prévenir les complications du traitement adjuvant ?
Un suivi médical régulier et une bonne hygiène peuvent aider à prévenir les complications.
Prévention des complicationsSuivi médicalHygiène
#3
Les complications sont-elles réversibles ?
Certaines complications peuvent être réversibles, mais d'autres peuvent être permanentes.
ComplicationsRéversibilitéEffets secondaires
#4
Quand signaler des complications au médecin ?
Signalez immédiatement tout symptôme inhabituel ou aggravation de l'état de santé.
Consultation médicaleSymptômesComplications
#5
Les complications varient-elles selon le type de traitement ?
Oui, les complications peuvent varier selon le type de médicament et le cancer traité.
Type de traitementComplicationsCancer
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour nécessiter un traitement adjuvant ?
Les facteurs incluent le stade avancé du cancer, l'âge et des antécédents familiaux.
Facteurs de risqueAntécédents familiauxStade du cancer
#2
Le mode de vie influence-t-il le besoin de traitement adjuvant ?
Oui, des habitudes comme le tabagisme ou une mauvaise alimentation peuvent augmenter les risques.
Mode de vieTabagismeAlimentation
#3
Les antécédents médicaux jouent-ils un rôle ?
Oui, des antécédents de cancer ou de maladies chroniques peuvent influencer le traitement.
Antécédents médicauxMaladies chroniquesCancer
#4
L'âge est-il un facteur de risque pour le traitement adjuvant ?
Oui, les patients plus âgés peuvent avoir un risque accru de récidive et nécessiter un traitement.
ÂgeRécidiveTraitement adjuvant
#5
Les facteurs environnementaux affectent-ils le besoin de traitement ?
Oui, l'exposition à des substances cancérigènes peut augmenter le risque de cancer.
Facteurs environnementauxSubstances cancérigènesRisque de cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Traitement médicamenteux adjuvant : Questions médicales les plus fréquentes",
"headline": "Traitement médicamenteux adjuvant : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Traitement médicamenteux adjuvant : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-20",
"dateModified": "2026-04-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Traitement médicamenteux adjuvant"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Traitement médicamenteux",
"url": "https://questionsmedicales.fr/mesh/D004358",
"about": {
"@type": "MedicalCondition",
"name": "Traitement médicamenteux",
"code": {
"@type": "MedicalCode",
"code": "D004358",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.319"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Traitement médicamenteux adjuvant",
"alternateName": "Chemotherapy, Adjuvant",
"code": {
"@type": "MedicalCode",
"code": "D017024",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Shinji Tsukamoto",
"url": "https://questionsmedicales.fr/author/Shinji%20Tsukamoto",
"affiliation": {
"@type": "Organization",
"name": "Department of Orthopaedic Surgery, Nara Medical University, Nara, Japan."
}
},
{
"@type": "Person",
"name": "Alberto Righi",
"url": "https://questionsmedicales.fr/author/Alberto%20Righi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy."
}
},
{
"@type": "Person",
"name": "Akira Kido",
"url": "https://questionsmedicales.fr/author/Akira%20Kido",
"affiliation": {
"@type": "Organization",
"name": "Department of Rehabilitation Medicine, Nara Medical University, Nara, Japan."
}
},
{
"@type": "Person",
"name": "Kanya Honoki",
"url": "https://questionsmedicales.fr/author/Kanya%20Honoki",
"affiliation": {
"@type": "Organization",
"name": "Department of Orthopaedic Surgery, Nara Medical University, Nara, Japan."
}
},
{
"@type": "Person",
"name": "Yuu Tanaka",
"url": "https://questionsmedicales.fr/author/Yuu%20Tanaka",
"affiliation": {
"@type": "Organization",
"name": "Department of Rehabilitation Medicine, Wakayama Professional University of Rehabilitation, Wakayama, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "PERIOPERATIVE CHEMOTHERAPY, ADJUVANT CHEMOTHERAPY AND ADJUVANT CHEMORADIOTHERAPY IN THE SURGICAL TREATMENT OF GASTRIC CANCER IN A HOSPITAL OF THE BRAZILIAN UNIFIED HEALTH SYSTEM.",
"datePublished": "2024-07-01",
"url": "https://questionsmedicales.fr/article/38958346",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/0102-6720202400017e1810"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adjuvant chemotherapy or no adjuvant chemotherapy? A prediction model for the risk stratification of recurrence or metastasis of nasopharyngeal carcinoma combining MRI radiomics with clinical factors.",
"datePublished": "2023-09-26",
"url": "https://questionsmedicales.fr/article/37751422",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0287031"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adjuvant Chemotherapy for Breast Cancer in Older Adult Patients.",
"datePublished": "2024-07-16",
"url": "https://questionsmedicales.fr/article/39050516",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2147/CIA.S470262"
}
},
{
"@type": "ScholarlyArticle",
"name": "Combination of neoadjuvant and adjuvant chemotherapy with FOLFOX compared with adjuvant chemotherapy in management of locally advanced rectal cancers: a randomized trial of a promising therapeutic approach.",
"datePublished": "2024-07-18",
"url": "https://questionsmedicales.fr/article/39026218",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12885-024-12634-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "The efficacy of adjuvant chemotherapy on the survival of early stage endometrial cancer.",
"datePublished": "2023-06-08",
"url": "https://questionsmedicales.fr/article/37343413",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejogrb.2023.06.004"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Thérapeutique",
"item": "https://questionsmedicales.fr/mesh/D013812"
},
{
"@type": "ListItem",
"position": 3,
"name": "Traitement médicamenteux",
"item": "https://questionsmedicales.fr/mesh/D004358"
},
{
"@type": "ListItem",
"position": 4,
"name": "Traitement médicamenteux adjuvant",
"item": "https://questionsmedicales.fr/mesh/D017024"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Traitement médicamenteux adjuvant - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Traitement médicamenteux adjuvant",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-04-29",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Traitement médicamenteux adjuvant",
"description": "Comment savoir si un traitement adjuvant est nécessaire ?\nQuels tests sont utilisés pour évaluer le besoin d'un traitement adjuvant ?\nQui décide du traitement adjuvant ?\nLe traitement adjuvant est-il standardisé ?\nQuels facteurs influencent le choix du traitement adjuvant ?",
"url": "https://questionsmedicales.fr/mesh/D017024#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Traitement médicamenteux adjuvant",
"description": "Quels symptômes peuvent indiquer un besoin de traitement adjuvant ?\nLe traitement adjuvant provoque-t-il des symptômes ?\nComment gérer les symptômes liés au traitement adjuvant ?\nLes symptômes varient-ils selon le type de cancer ?\nQuand consulter un médecin pendant le traitement adjuvant ?",
"url": "https://questionsmedicales.fr/mesh/D017024#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Traitement médicamenteux adjuvant",
"description": "Le traitement adjuvant aide-t-il à prévenir le cancer ?\nQuelles mesures préventives peuvent être prises après un traitement ?\nLe suivi médical est-il important après un traitement adjuvant ?\nLes vaccinations sont-elles recommandées après un traitement adjuvant ?\nComment le soutien psychologique aide-t-il après un traitement ?",
"url": "https://questionsmedicales.fr/mesh/D017024#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Traitement médicamenteux adjuvant",
"description": "Quels médicaments sont utilisés en traitement adjuvant ?\nQuelle est la durée d'un traitement adjuvant ?\nLe traitement adjuvant est-il toujours efficace ?\nComment le traitement adjuvant est-il administré ?\nY a-t-il des alternatives au traitement adjuvant ?",
"url": "https://questionsmedicales.fr/mesh/D017024#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Traitement médicamenteux adjuvant",
"description": "Quelles sont les complications possibles du traitement adjuvant ?\nComment prévenir les complications du traitement adjuvant ?\nLes complications sont-elles réversibles ?\nQuand signaler des complications au médecin ?\nLes complications varient-elles selon le type de traitement ?",
"url": "https://questionsmedicales.fr/mesh/D017024#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Traitement médicamenteux adjuvant",
"description": "Quels sont les facteurs de risque pour nécessiter un traitement adjuvant ?\nLe mode de vie influence-t-il le besoin de traitement adjuvant ?\nLes antécédents médicaux jouent-ils un rôle ?\nL'âge est-il un facteur de risque pour le traitement adjuvant ?\nLes facteurs environnementaux affectent-ils le besoin de traitement ?",
"url": "https://questionsmedicales.fr/mesh/D017024#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment savoir si un traitement adjuvant est nécessaire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La nécessité est déterminée par le stade du cancer et les caractéristiques tumorales."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer le besoin d'un traitement adjuvant ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens d'imagerie, des biopsies et des marqueurs tumoraux sont souvent utilisés."
}
},
{
"@type": "Question",
"name": "Qui décide du traitement adjuvant ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'équipe médicale, incluant oncologues et chirurgiens, prend cette décision ensemble."
}
},
{
"@type": "Question",
"name": "Le traitement adjuvant est-il standardisé ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il varie selon le type de cancer et les caractéristiques individuelles du patient."
}
},
{
"@type": "Question",
"name": "Quels facteurs influencent le choix du traitement adjuvant ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le type de cancer, le stade, l'âge et l'état de santé général du patient sont pris en compte."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un besoin de traitement adjuvant ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes de récidive ou de progression de la maladie peuvent signaler ce besoin."
}
},
{
"@type": "Question",
"name": "Le traitement adjuvant provoque-t-il des symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme la fatigue, nausées et douleurs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment gérer les symptômes liés au traitement adjuvant ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments et des thérapies complémentaires peuvent aider à soulager les symptômes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de cancer ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes et effets secondaires dépendent du type de cancer et du traitement."
}
},
{
"@type": "Question",
"name": "Quand consulter un médecin pendant le traitement adjuvant ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez si les symptômes s'aggravent ou si de nouveaux symptômes apparaissent."
}
},
{
"@type": "Question",
"name": "Le traitement adjuvant aide-t-il à prévenir le cancer ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il ne prévient pas le cancer, mais réduit le risque de récidive après un traitement initial."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives peuvent être prises après un traitement ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, suivi médical régulier et dépistages peuvent aider à la prévention."
}
},
{
"@type": "Question",
"name": "Le suivi médical est-il important après un traitement adjuvant ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le suivi permet de détecter précocement toute récidive ou effet secondaire."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles recommandées après un traitement adjuvant ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent être recommandées pour renforcer le système immunitaire."
}
},
{
"@type": "Question",
"name": "Comment le soutien psychologique aide-t-il après un traitement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il aide à gérer l'anxiété et le stress liés à la maladie et au traitement."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés en traitement adjuvant ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des chimiothérapies, thérapies ciblées ou hormonales peuvent être prescrites."
}
},
{
"@type": "Question",
"name": "Quelle est la durée d'un traitement adjuvant ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée varie, mais elle est généralement de plusieurs mois à un an selon le cancer."
}
},
{
"@type": "Question",
"name": "Le traitement adjuvant est-il toujours efficace ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il réduit le risque de récidive, mais son efficacité varie selon les cas individuels."
}
},
{
"@type": "Question",
"name": "Comment le traitement adjuvant est-il administré ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être administré par voie intraveineuse, orale ou sous-cutanée selon le médicament."
}
},
{
"@type": "Question",
"name": "Y a-t-il des alternatives au traitement adjuvant ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques ou des traitements expérimentaux peuvent être envisagés."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du traitement adjuvant ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme infections, fatigue chronique et troubles sanguins peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications du traitement adjuvant ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et une bonne hygiène peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Quand signaler des complications au médecin ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Signalez immédiatement tout symptôme inhabituel ou aggravation de l'état de santé."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le type de traitement ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent varier selon le type de médicament et le cancer traité."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour nécessiter un traitement adjuvant ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le stade avancé du cancer, l'âge et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le besoin de traitement adjuvant ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme ou une mauvaise alimentation peuvent augmenter les risques."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de cancer ou de maladies chroniques peuvent influencer le traitement."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour le traitement adjuvant ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients plus âgés peuvent avoir un risque accru de récidive et nécessiter un traitement."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux affectent-ils le besoin de traitement ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des substances cancérigènes peut augmenter le risque de cancer."
}
}
]
}
]
}
Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.
Publications dans "Traitement médicamenteux adjuvant" :
Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA. Electronic address: hwakelee@stanford.edu.
Publications dans "Traitement médicamenteux adjuvant" :
Medical Oncology Department, Hospital Universitario Infanta Sofía, Avenida de Europa 34, 28702, San Sebastián de Los Reyes, Madrid, Spain. cgomezr@salud.madrid.org.
Publications dans "Traitement médicamenteux adjuvant" :
Despite the preference for multimodal treatment for gastric cancer, abandonment of chemotherapy treatment as well as the need for upfront surgery in obstructed patients brings negative impacts on the ...
To identify advantages, prognostic factors, complications, and neoadjuvant and adjuvant therapies survival in gastric cancer treatment in SUS setting....
The retrospective study included 81 patients with gastric adenocarcinoma who underwent treatment according to INT0116 trial (adjuvant chemoradiotherapy), CLASSIC trial (adjuvant chemotherapy), FLOT4-A...
Patients were grouped into FLOT4-AIO (26 patients), CLASSIC (25 patients), and INT0116 (30 patients). The average age was 61 years old. More than 60% of patients had pathological stage III. The treatm...
The treatment strategy for gastric cancer varies according to the need for initial surgery. The CLASSIC subgroup had better overall survival and disease-free survival. The INT0116 regimen also protect...
Dose adjuvant chemotherapy (AC) should be offered in nasopharyngeal carcinoma (NPC) patients? Different guidelines provided the different recommendations....
In this retrospective study, a total of 140 patients were enrolled and followed for 3 years, with 24 clinical features being collected. The imaging features on the enhanced-MRI sequence were extracted...
In total, 960 imaging features were extracted. A CRM was constructed from nine features (seven imaging features and two clinical factors). In the training cohort, the area under curve (AUC) of CRM for...
Considering increasing RMFR, a prediction model for NPC based on two clinical factors and seven imaging features suggested the AC needs to be added to patients in the high-risk group and not in the lo...
Decision-making regarding adjuvant chemotherapy for older adults with breast cancer is a challenge because older adult patients often have poor physical health, frailty, and age-related comorbidities,...
Colorectal cancer (CRC) is a significant malignancy with widespread implications. Despite progress in surgical interventions for rectal cancer, improvements in overall prognosis remain disproportionat...
This randomised clinical trial assessed 286 patients with LARC in two paralleled groups. Group A underwent six courses of neoadjuvant MFOLFOX chemotherapy, chemoradiation, surgery, and six adjuvant ch...
Group A had significantly lower local recurrence (11.64%) than Group B (21.74%, P = 0.025). The distant metastasis rate in Group A (8.90%) was lower than in Group B (20.29%) but was not significant (p...
This innovative strategy for LARC showed promising results with lower local recurrence and higher rates of downstaging and pCR. Treatment side effects were similar in both groups but less frequent in ...
This trial was registered on 2023-12-08 within the IRCT.IR database under the number IRCT20210308050628N1....
No consensus exists on the adjuvant chemotherapy for the International Federation of Gynecology and Obstetrics (FIGO) Stage I-II endometrial cancer with risk factors for recurrence. This study evaluat...
We conducted a retrospective chart review of patients with FIGO Stage I-II endometrial cancer with recurrence risk factors. The patients received no adjuvant therapy at the National Cancer Center Hosp...
Six hundred thirty-eight patients with endometrial cancer were identified. Of these, 118 met the inclusion criteria, 321 were excluded from NCCH, while 49 met the inclusion criteria, and 150 were excl...
This study did not show that adjuvant chemotherapy for FIGO Stages I-II endometrial cancer with recurrence risk factors has survival benefit. Further large-scale studies are necessary to validate our ...
A recovery period between surgery and initiation of adjuvant chemotherapy (AC) is common in patients with upper tract urothelial carcinoma (UTUC), which can progress after a relatively long time. Ther...
Clinical data for 428 UTUC patients diagnosed with transitional cell carcinoma with postoperatively confirmed pathological stages, muscle-invasive or greater-stage (pT2-4) disease, any nodal status, a...
A total of 428 patients were analyzed in the study, including 132 individuals who underwent the AC procedure with platinum in combination with gemcitabine within 90 days after RNU and 296 patients who...
The present study data supported the finding that a platinum-based combination with gemcitabine regimen initiated postoperatively significantly improved OS and CSS in patients with UTUC at stages ≥pT2...
This study aimed to elucidate the difficulty of adjuvant chemotherapy administration in patients with biliary tract carcinoma (BTC)....
Clinical data of patients with BTC who underwent curative-intent surgery were retrospectively analyzed. The eligible patients were stratified into two groups according to the presence or absence of ad...
Among 168 eligible patients, 141 (83.9%) received adjuvant chemotherapy (adjuvant group), while 27 (16.1%) did not (non-adjuvant group). The most common surgical procedure was pancreaticoduodenectomy ...
Hepatectomy with BDR and subsequent refractory bile leak can be the obstacle to adjuvant chemotherapy administration in patients with BTC....
Although the importance of adjuvant chemotherapy (AC) has been recognized in pancreatic cancer (PC) patients, there are few studies to address the underlying mechanisms of failure to complete AC. This...
The benefits of chemotherapy in stage II colon cancer remain unclear, but it is recommended for high-risk stage II disease. Which patients receive chemotherapy and its impact on survival remains undet...
The National Cancer Database was surveyed between 2004 and 2016 for stage II colon cancer patients. Patients were categorized as high- or average-risk as defined by the National Comprehensive Cancer N...
Overall, 84,424 patients met the inclusion criteria. A total of 34,868 patients were high-risk and 49,556 were average-risk. In high-risk patients, the risk factors for not receiving chemotherapy incl...
Factors associated with not receiving chemotherapy in high-risk stage II colon cancers included increasing age, medical comorbidities, increasing distance from the treatment facility, and lack of insu...
Oxaliplatin is a third-generation platinum-based antineoplastic drug that is widely used to treat patients with colorectal cancer. Reported adverse reactions include hepatic sinusoidal obstruction syn...
We report a case of suspected oxaliplatin-induced liver cirrhosis, an adverse reaction that has not been previously reported....
A 50-year-old Chinese man was diagnosed with rectal cancer and underwent laparoscopic radical rectal cancer surgery. The patient had a history of schistosomiasis, but history and serology showed no ev...
Oxaliplatin-induced cirrhosis may be a serious complication and should be discontinued based on clinical evidence....